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Targeting Protein-Tyrosine Phosphatases in Breast Cancer
Nicola Aceto and Mohamed Bentires-Alj:
Most signaling pathways are modulated by 
reversible tyrosine phosphorylation, which is regulated by 
the opposing actions of protein-tyrosine kinases (PTKs) 
and protein-tyrosine phosphatases (PTPs) [1]. Abnormal 
tyrosine phosphorylation underlies various diseases 
of deregulated growth and differentiation, including 
cancer [1]. Although the involvement of several PTKs 
in malignancy has been studied extensively (e.g., ErbB2/
HER2 in breast cancer), elucidation of the participation 
of specific PTPs in this disease has only started recently. 
Here, we summarize the activities of two major PTPs, 
SHP2 [2] and PTP1B [3], in breast cancer, highlight 
their potential as targets for breast cancer treatment or 
prevention, and discuss the technical challenges facing the 
development of specific PTP inhibitors.
The tyrosine-phosphatase SHP2 has been shown to 
play a broad role in development and cancer, as well as in 
the regulation of cell fate and the activation of a number 
of signaling networks downstream of receptor tyrosine-
kinases and cytokine receptors [4]. However, its merits as 
a drug target for breast cancer and its role in breast tumor 
progression have not been demonstrated previously. We 
have discovered a fundamental contribution of SHP2 to 
breast cancer progression and the propagation of tumor-
initiating cells (TICs) in vivo [2]. Mechanistically, SHP2 
activates transcription factors such as c-Myc and ZEB1 
and induces the expression of a set of “SHP2 signature” 
genes found co-activated in a subset of human primary 
breast tumors and associated with invasive behavior 
and poor prognosis. SHP2, acting via c-Myc, induces 
the expression of the suppressor of miRNA biogenesis 
LIN28B which blocks the maturation of the tumor-
suppressor microRNA let-7 [2]. These results provide 
new insights into signaling networks promoting tumor 
progression and TIC maintenance, as well as a rationale 
for developing SHP2-targeting agents for breast cancer 
therapy. In addition, the identification of a set of “SHP2 
signature” genes, activated in the presence of SHP2 
signaling, could provide a powerful tool to identify tumors 
eligible for SHP2-targeted therapy.
A further major PTP family member, PTP1B, is a 
well-established metabolic regulator that is associated with 
cancer [5]. For example, PTP1B knockout mice are insulin 
and leptin hypersensitive, which contributes to obesity-
resistance under high-fat diet conditions [6, 7]. Moreover, 
whole-body deletion of PTP1B in mice delays or protects 
against HER2/Neu-induced mammary carcinogenesis [8, 
9]. Recently, we found that deletion of PTP1B specifically 
in the mammary epithelium also delays the onset of HER2/
Neu-evoked breast tumors, suggesting a cell-autonomous 
role for PTP1B in the onset of this disease [3]. However, 
deletion of PTP1B in established mouse mammary tumors 
or shRNA-mediated depletion of PTP1B in human breast 
cancer cell lines grown as xenografts did not affect tumor 
growth [3]. These results indicate that targeting PTP1B 
may be effective in breast cancer prevention but not in the 
treatment of advanced breast cancers of the HER2-positive 
subtype.
The  latest  findings  on  SHP2  and  PTP1B  clearly 
indicate  that  many  patients  would  benefit  from  the 
design of specific inhibitors targeting these phosphatases. 
Unfortunately, the development of PTP inhibitors has 
encountered significant technical challenges. For example, 
interaction of inhibitor compounds with the PTP domain 
requires a high polarity, which is associated unfortunately 
with reduced cell permeability and bioavailability. To 
some extent, this problem can be addressed by the use 
of prodrugs or other chemical modifications. In addition, 
PTPs are highly susceptible to oxidation of the catalytic 
cysteine residue in the phosphatase domain, which leads 
to a conformational change at the active site and may limit 
binding efficacy. Taking advantage of this property, recent 
studies suggest that therapeutics that stabilize the oxidized 
form of the phosphatase and lock it in an inactive state 
may represent an alternative way for inhibiting PTPs [10]. 
Another important issue is the need to develop selective 
compounds that do not bind structurally similar PTPs, 
such as SHP1 (in the case of SHP2) or TC-PTP (in the 
case of PTP1B). This is a challenging aspect since PTPs 
share highly conserved phosphatase domains. However, 
specific PTP subpockets surrounding the active site can 
be targeted to enhance selectivity. Lastly, although these 
technical challenges may be overcome, there remains the 
challenge of identifying specific PTP substrates that can be 
used as biomarkers of the response to the inhibitor.
In conclusion, we are starting to uncover important 
activities of PTPs in breast cancer initiation, progression 
and maintenance. Studies of SHP2 and PTP1B have 
exposed them as potentially important targets for the 
treatment or prevention of breast cancer, not to mention 
the importance of PTP1B in diabetes. However, the 
appropriateness  of  specific  inhibitors  has  to  be  fully 
confirmed, especially given the differential involvement 
of PTPs in an organ-dependent fashion. Crucial issues for 
future studies include the participation of other PTPs in 
tissue development and maintenance as well as cancer, and Oncotarget 2012; 3:  514-515 515 www.impactjournals.com/oncotarget
the signaling networks perturbed by PTP inactivation. This 
approach may lead to the discovery of novel signaling 
mechanisms regulated by PTPs and a better understanding 
of cancer-associated pathways.
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